Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX:PBT)
Filing Type: Form 6-K (Appendix 4D Interim Financial Report)
Reporting Period: Half-year ended 31 December 2014
Filing Date: 24 February 2015
Business Overview: Prana is a development-stage medical biotechnology company focused on research into Alzheimer's Disease and other major age-related degenerative disorders. The company has no commercial product revenue and relies on interest income, government grants, and capital raising to fund operations.
Key Financial Metrics
| Metric | Half-Year 2014 (A$) | Half-Year 2013 (A$) |
|---|---|---|
| Revenue (Interest income) | 92,581 | 189,588 |
| Other Income (R&D Tax Concession & Grants) | 3,331,429 | 1,460,480 |
| Net Loss (After tax) | (1,252,695) | (7,928,392) |
| Loss Per Share (Basic & Diluted) | (0.26) cents | (1.97) cents |
| Cash and Cash Equivalents | 29,053,056 | 19,300,061 |
| Net Tangible Assets per Share | 7.47 cents | 7.71 cents |
| Operating Cash Flow | (8,411,407) | (7,435,475) |
Debt and Liquidity: The company reported total liabilities of A$3,297,682, primarily consisting of trade payables (A$2.64m) and provisions. There is no long-term debt. The company holds a significant trade receivable of A$10.43 million from the Australian Tax Office related to R&D tax incentives.
Material Changes vs. Prior Period
- Loss Reduction: The net loss decreased significantly by 84.2% to A$1.25 million, compared to A$7.93 million in the prior period. This improvement was driven by a foreign exchange gain of A$3.25 million, an increase in R&D tax concession income, and reduced R&D expenditure.
- Revenue Decline: Revenue from ordinary activities (interest income) fell 51.2% to A$92,581 due to lower cash balances in interest-bearing accounts.
- Cash Position: Cash and cash equivalents decreased by A$5.1 million to A$29.05 million, reflecting operating outflows of A$8.4 million, partially offset by a foreign exchange gain on cash balances.
- Capital Structure: The company issued 110,000 new shares and 180,000 shares upon option exercise during the period. Net tangible assets per share declined slightly from 7.71 cents to 7.47 cents.
Outlook, Risks, and Management Commentary
Operational Updates
- Alzheimer's (PBT2): The 12-month Open Label Extension to the Phase II 'IMAGINE' trial completed dosing. Final results are expected in Q2 2015. No safety concerns were identified by the Data Safety Monitoring Board.
- Huntington's Disease (PBT2): Phase II results were published in The Lancet Neurology, showing safety and promising indications of cognitive improvement in executive function. However, the FDA issued a Partial Clinical Hold in February 2015 based on non-clinical (animal) findings, limiting the dose to less than the preferred 250mg target. The company is discussing options with the FDA to resolve this.
- PBT434: Development for movement disorders progressed with completed animal toxicology studies. Phase I trials are anticipated to commence in late 2015 or early 2016.
Capital Raising and Liquidity
The company maintains a shelf registration (Form F-3) for up to US$50 million in securities. Subsequent to the reporting period, the company sold 3.82 million ADRs for gross proceeds of approximately A$5.69 million via an "at-the-market" facility. Directors believe current cash plus subsequent inflows are sufficient for at least 12 months.
Risks and Contingencies
- Regulatory Risk: The FDA Partial Clinical Hold on the Huntington's Disease program poses a risk to the timeline and design of the planned Phase III trial.
- Funding Risk: As a development-stage company, Prana relies on continued capital raising and R&D tax incentives. A reduction in the R&D tax offset rate (from 45% to 43.5%) could impact future income.
- Going Concern: While the company is currently solvent, future viability depends on successful clinical outcomes and the ability to raise additional funds.
Investor Verification Checklist
- FDA Partial Clinical Hold: Verify the status of discussions with the FDA regarding the PBT2 Huntington's Disease program and the timeline for resolving the dose limitation.
- R&D Tax Receivables: Confirm the expected collection dates for the A$10.43 million receivable from the Australian Tax Office, which is critical for liquidity.
- Cash Burn Rate: Monitor the operating cash outflow (A$8.4m for the half-year) against the current cash balance (A$29.1m) to assess runway without further capital raises.
- Capital Raising Activity: Track the utilization of the US$50 million ATM facility and any dilution from future share issuances.
- Clinical Data Release: Await the final results of the Alzheimer's 'IMAGINE' extension study expected in Q2 2015.